Kiyatec

Kiyatec develops 3D phenotypic cell-based assays and diagnostic solutions for predicting patient response to cancer drug treatment. The company creates live 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials, and clinical diagnostics. This information helps in drug selection, minimizing clinical trial failures, and maximizing patient outcomes. Founded in 2005 and headquartered in Pendleton, Kiyatec has raised approximately $29.5M in Series C funding from investors including Esperante, SCRA, Seae Ventures, LabCorp, Bruker, HHS, and Inova. The company's 3D cell culture technology more accurately replicates the in vivo tumor microenvironment compared to traditional 2D cell cultures, providing clinically relevant predictions of how individual patients' tumors will respond to specific chemotherapy regimens, supporting the shift toward personalized oncology treatment.